V
Vojtech Kulvait
Researcher at First Faculty of Medicine, Charles University in Prague
Publications - 19
Citations - 363
Vojtech Kulvait is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Computer science & Medicine. The author has an hindex of 7, co-authored 12 publications receiving 300 citations. Previous affiliations of Vojtech Kulvait include Charles University in Prague.
Papers
More filters
Journal ArticleDOI
MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia
Karin Vargova,Nikola Curik,Pavel Burda,Petra Basova,Vojtech Kulvait,Vit Pospisil,Filipp Savvulidi,Juraj Kokavec,Emanuel Necas,Adela Berkova,Petra Obrtlikova,Josef Karban,Marek Mráz,Šárka Pospíšilová,Jiri Mayer,Marek Trneny,Jiri Zavadil,Jiri Zavadil,Tomas Stopka +18 more
TL;DR: Evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL patients is presented and evidence of oncogenic activities of MYB in B- CLL that include its stimulatory role in MIR155HG transcription is provided.
Journal ArticleDOI
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase
Katerina Machova Polakova,Vojtech Kulvait,Adela Benesova,Jana Linhartova,Hana Klamova,Monika Jaruskova,Caterina De Benedittis,Torsten Haferlach,Michele Baccarani,Giovanni Martinelli,Tomas Stopka,Thomas Ernst,Andreas Hochhaus,Alexander Kohlmann,Simona Soverini +14 more
TL;DR: It is pointed out, that next-generation deep sequencing, coupled with a robust bioinformatics approach for mutation calling, may be just in place to ensure reliable detection of emerging BCR-ABL1 mutations, allowing early therapy switch and selection of the most appropriate therapy.
Journal ArticleDOI
The ISWI ATPase Smarca5 (Snf2h) Is Required for Proliferation and Differentiation of Hematopoietic Stem and Progenitor Cells.
Juraj Kokavec,Juraj Kokavec,Tomas Zikmund,Filipp Savvulidi,Vojtech Kulvait,Winfried Edelmann,Arthur I. Skoultchi,Tomas Stopka +7 more
TL;DR: Deleted Smarca5 at the onset of definitive hematopoiesis (Vav1‐iCre) and observed that animals die during late fetal development due to anemia and 4‐hydroxytamoxifen‐mediated deletion in the ex vivo cultures confirmed its requirement for erythroid cell proliferation.
Journal ArticleDOI
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Magdalena Klanova,Lucie Lorkova,Ondrej Vit,Bokang Maswabi,Jan Molinsky,Jana Pospisilova,Petra Vockova,Cory Mavis,Lucie Lateckova,Vojtech Kulvait,Dana Vejmelkova,Radek Jaksa,Francisco Hernandez,Marek Trneny,Martin Vokurka,Jiri Petrak,Pavel Klener +16 more
TL;DR: Acquired resistance of MCL cells to araC is associated with downregulation of DCK, enzyme of the nucleotide salvage pathway responsible for the first phosphorylation (=activation) of most nucleoside analogs used in anti-cancer therapy.
Journal ArticleDOI
Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.
Magdalena Klanova,Tomáš Soukup,Radek Jaksa,Jan Molinsky,Lucie Lateckova,Bokang Maswabi,Dana Prukova,Jana Brezinova,Kyra Michalova,Petra Vockova,Francisco J. Hernandez-Ilizaliturri,Vojtech Kulvait,Jan Zivny,Martin Vokurka,Emanuel Necas,Marek Trneny,Pavel Klener +16 more
TL;DR: It is demonstrated that engrafted MCL cells displayed complex changes of GEP, protein expression, and sensitivity to cytotoxic agents when compared with controls, and could be used to test the therapeutic activity of systemic chemotherapy, monoclonal antibodies, or angiogenesis inhibitors.